Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANTARES PHARMA, INC.

(ATRS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Antares Pharma : Earnings Flash (ATRS) ANTARES PHARMA Reports Q2 Revenue $45M, vs. Street Est of $43.3M

08/05/2021 | 07:17am EDT


ę MT Newswires 2021
All news about ANTARES PHARMA, INC.
08:23aANTARES PHARMA ANNOUNCES APPOINTMENT OF CARMEN VOLKART TO ITS BOARD OF DIRECTORS - Form..
PU
08:15aANTARES PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
08:02aAntares Pharma Announces Appointment of Carmen Volkart to its Board of Directors
GL
10/25ANTARES PHARMA : Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of..
GL
10/25Antares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting o..
GL
10/21ANTARES PHARMA : to Report Third Quarter 2021 Financial and Operating Results
GL
10/21Antares Pharma to Report Third Quarter 2021 Financial and Operating Results
GL
10/19ANTARES PHARMA : Enters into exclusive license agreement with lipocine for tlando in u.s.
AQ
10/19LIPOCINE : And Antares Pharma Enter Into U.S. Licensing Agreement To Commercialize TLANDO
AQ
10/18LIPOCINE : Signs Deal with Antares Pharma for Commercialization of Tlando in the US; Share..
MT
More news
Analyst Recommendations on ANTARES PHARMA, INC.
More recommendations
Financials (USD)
Sales 2021 187 M - -
Net income 2021 17,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 34,3x
Yield 2021 -
Capitalization 591 M 591 M -
Capi. / Sales 2021 3,17x
Capi. / Sales 2022 2,55x
Nbr of Employees 185
Free-Float 97,8%
Chart ANTARES PHARMA, INC.
Duration : Period :
Antares Pharma, Inc. Technical Analysis Chart | ATRS | US0366421065 | MarketScreener
Technical analysis trends ANTARES PHARMA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 3,48 $
Average target price 6,64 $
Spread / Average Target 90,9%
EPS Revisions
Managers and Directors
Robert F. Apple President, Chief Executive Officer & Director
Fred M. Powell Chief Financial Officer & Executive Vice President
Leonard S. Jacob Chairman
Jonathan S. Jaffe Vice President-Clinical & Medical Affairs
Peter C. Richardson Chief Medical Officer & Executive VP-Research
Sector and Competitors
1st jan.Capi. (M$)
ANTARES PHARMA, INC.-12.78%591
ABBOTT LABORATORIES16.64%226 407
MEDTRONIC PLC4.58%164 862
BECTON, DICKINSON AND COMPANY-2.09%70 362
HOYA CORPORATION18.01%56 045
DEXCOM, INC.51.07%54 038